Elite Pharmaceuticals starts second trial of once-daily oxycodone

By Elaine Rigoli

Tampa, Fla., May 25 - Elite Pharmaceuticals, Inc. said it has started a pilot phase 1 pharmacokinetic study evaluating ELI-154, a once-daily oxycodone HCl.

This product is intended to deliver more consistent levels of the drug to patients who take the drug for chronic pain.

Currently, there is no once-daily oxycodone on the market, the company said in a news release.

This is the second study for ELI-154 and the company's second oxycodone HCl product in clinical trials.

The first pilot phase 1 study for this product demonstrated proof of concept, the release said.

This second study will evaluate variables to optimize the formulation. Upon completion of this study, Elite intends to enter into a phase 2 study, which it will start by the end of 2006, the release said.

Based in Northvale, N.J., Elite Pharmaceuticals is a specialty pharmaceutical company principally engaged in the development and manufacturing of oral controlled-release products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.